All In Biotech

Drug Trial Radar · NCT06493045

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

A Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled, Phase I, First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

May 16, 2024

Primary completion

Feb 7, 2025

Study completion Feb 7, 2025

Sponsor

Sponsor type
Industry
Collaborators
Michael J. Fox Foundation for Parkinson's Research
First posted
Jul 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.

Conditions

  • Not Determined

Interventions

  • IRL757Drug

    IRL757 capsule

  • PlaceboDrug

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of Frequency, Seriousness and Intensity of Adverse EventsTime frame: Until 5-10 days after IMP administration
  2. Description of Physical Examination FindingsTime frame: Until 5-10 days after IMP administration
  3. Description of Electrocardiogram FindingsTime frame: Until 5-10 days after IMP administration
  4. Description of Vital Signs FindingsTime frame: Until 5-10 days after IMP administration
  5. Description of Safety Laboratory MeasurementsTime frame: Until 5-10 days after IMP administration
  6. Description of C-SSRS (Columbia Suicide Severity Rating Scale) FindingsTime frame: Until 5-10 days after IMP administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTC Clinical Trial Consultants AB, Uppsala University Hospital

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.